Pankaj Jain, MD
Pulmonary Disease · Olympia Fields, ILNPI 1215996301
Payments from drug & device makers
Across 240 payments — averaging $14.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$924
- AstraZeneca$647
- Boehringer Ingelheim$605
- Mylan Specialty L.p.$300
- Regeneron Healthcare Solutions, Inc.$155
- Philips North America LLC$128
- plus $777 from 21 others
What the payments were for
- Food & beverage$3,529100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 92 | $924 |
| AstraZeneca | 37 | $647 |
| Boehringer Ingelheim | 38 | $605 |
| Mylan Specialty L.p. | 19 | $300 |
| Regeneron Healthcare Solutions, Inc. | 8 | $155 |
| Philips North America LLC | 5 | $128 |
| Johnson & Johnson | 7 | $128 |
| Electromed, Inc. | 6 | $81 |
| Verona Pharma, Inc. | 3 | $60 |
| Mallinckrodt Hospital Products Inc. | 2 | $53 |
| Sanofi | 3 | $51 |
| Pulmonx Corporation | 2 | $47 |
| Sunovion Pharmaceuticals Inc. | 2 | $45 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| Merck | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Harmony Biosciences LLC | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Inogen, Inc. | 1 | $21 |
| Viatris Specialty LLC | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Advanced Respiratory, Inc | 1 | $16 |
| Pfizer | 1 | $14 |
| Baxter Healthcare | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$3,536 in reported general payments places this provider in the 60th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 162 | $217,834 |
| OfevNintedanib Esylate | 12 | $164,212 |
| Breo ElliptaFluticasone/Vilanterol | 142 | $122,858 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 91 | $98,754 |
| Spiriva RespimatTiotropium Bromide | 46 | $52,646 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 47 | $52,277 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $19,909 |
| EliquisApixaban | 12 | $15,677 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 55 | $13,530 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $12,699 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 193 | $12,231 |
| Wixela InhubFluticasone Propion/Salmeterol | 27 | $9,414 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $9,256 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $8,352 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $7,940 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $924 | $452,145408 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $605 | $277,076119 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $647 | $34,09437 claims |
| PfizerEliquis | $14 | $15,67712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Olympia Fields
- Douglas HogarthChicago$3.1M
- Manu JainChicago$1.9M
- Momen WahidiChicago$1.2M
- Shashi BellamEvanston$1.2M
- Marilyn GlassbergMaywood$1000K
- Steven WhiteChicago$989K
- Ravi KalhanChicago$831K
- Patrick WhittenPeoria$812K
- Jane Dematte DamicoChicago$811K
- Septimiu MurguChicago$804K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.